Global Blood Stream Infection Testing Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Blood stream infection testing is a medical technique that is performed to figure out infections such as bacterial, fungal, or other that are present in an individual's bloodstream. The rising incidences of abdominal infection, bloodstream infections, chronic diseases, and dental infection, increasing geriatric population, coupled with the growing awareness of the significance of blood infection testing are the key factors burgeoning the global market growth. According to the National Center for Biotechnology Information report 2022, it was estimated that approximately 250,000 bloodstream infections occur per year. Also, it is majorly associated with the presence of intravascular devices. Thereby, the growing prevalence of bloodstream infections among the population is exhibiting a positive influence on the growth of the market across the globe. However, high maintenance costs and unavailability of insurance and reimbursement policies are hindering the market growth over the forecast period of 2022-2028. Also, the rising investment in R&D activities and increasing demand for technologically advanced diagnostic tests are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Blood Stream Infection Testing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the presence of advanced medical facilities and growing expenditure on R&D activities. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the increasing geriatric population, as well as high availability of developed products by the key market players, would create lucrative growth prospects for the Blood Stream Infection Testing Market across the Asia-Pacific region.

Major market players included in this report are:

Thermo Fisher Scientific, Inc.

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

becton dickinson medical devices co. ltd., suzhou

bioMerieux SA

cepheid

Luminex Corporation

Accelerate Diagnostics Inc.

AdvanDx

Bruker Corporation

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product Technologys of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:

Culture-based

Molecular

Proteomic

By Product:

Instruments

Consumables

Software and Services

By Technique:

Conventional

Automated

By Application:

Bacterial

Fungal

Mycobacterial

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Blood Stream Infection Testing Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors